INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
Public company

CADLCandel Therapeutics, Inc.

CIK 0001841387

EDGAR filingsOpen in network
Disclosed transactions14
Buys / sells0 / 5
Max Insider Score26
Connections10with evidence

CADL · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
10
TP
Tak Paul PeterDirector, Chief Executive Officer
CADLCandel Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$194K
125.0K sh
Sep 10, 2026Sep 11, 2026
traded Sep 10, 2026
+1dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2836 · Biological Products, (No Diagnostic Substances) · Nov 4, 2026
  • ← Insider ofevidence
    Tak Paul PeterDirector, Chief Executive Officer · Sep 11, 2026
  • ← Insider ofevidence
    Barone FrancescaChief Scientific Officer · Jul 1, 2026
  • ← Insider ofevidence
    Tyagarajan SeshuChief Technology Officer · Jul 1, 2026
3
TP
Tak Paul PeterDirector, Chief Executive Officer
CADLCandel Therapeutics, Inc.
Option exercise · 10b5-1 plan
M
—
125.0K sh
Sep 10, 2026
Sep 11, 2026
traded Sep 10, 2026
+1d
SEC FORM 4

Evidence

15
TP
Tak Paul PeterDirector, Chief Executive Officer
CADLCandel Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$621K
59.4K sh
Sep 11, 2026Sep 11, 2026
traded Sep 11, 2026
+0dSEC FORM 4

Evidence

26
TP
Tak Paul PeterDirector, Chief Executive Officer
CADLCandel Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$2.54M
220.9K sh
Sep 10, 2026Sep 11, 2026
traded Sep 10, 2026
+1dSEC FORM 4

Evidence

8
TS
Tyagarajan SeshuChief Technology Officer
CADLCandel Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$84K
7,000 sh
Aug 17, 2026Aug 19, 2026
traded Aug 17, 2026
+2dSEC FORM 4

Evidence

21
BF
Barone FrancescaChief Scientific Officer
CADLCandel Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$236K
23.4K sh
Jun 29, 2026Jul 1, 2026
traded Jun 29, 2026
+2dSEC FORM 4

Evidence

9
LN
Loggia NicolettaDirector
CADLCandel Therapeutics, Inc.
Grant or award
A$3,291
381 sh
Jun 30, 2026Jul 1, 2026
traded Jun 30, 2026
+1dSEC FORM 4

Evidence

17
TS
Tyagarajan SeshuChief Technology Officer
CADLCandel Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$70K
7,000 sh
Jun 29, 2026Jul 1, 2026
traded Jun 29, 2026
+2dSEC FORM 4

Evidence

9
GR
Gaeta ReneeDirector
CADLCandel Therapeutics, Inc.
Grant or award
A—
32.0K sh
Jun 23, 2026Jun 24, 2026
traded Jun 23, 2026
+1dSEC FORM 4

Evidence

9
ND
Nguyen DiemDirector
CADLCandel Therapeutics, Inc.
Grant or award
A—
32.0K sh
Jun 23, 2026Jun 24, 2026
traded Jun 23, 2026
+1dSEC FORM 4

Evidence

9
NJ
Nabel Gary J.Director
CADLCandel Therapeutics, Inc.
Grant or award
A—
32.0K sh
Jun 23, 2026Jun 24, 2026
traded Jun 23, 2026
+1dSEC FORM 4

Evidence

9
MC
Martell ChristopherDirector
CADLCandel Therapeutics, Inc.
Grant or award
A—
32.0K sh
Jun 23, 2026Jun 24, 2026
traded Jun 23, 2026
+1dSEC FORM 4

Evidence

9
LN
Loggia NicolettaDirector
CADLCandel Therapeutics, Inc.
Grant or award
A—
32.0K sh
Jun 23, 2026Jun 24, 2026
traded Jun 23, 2026
+1dSEC FORM 4

Evidence

9
RM
Radhakrishnan MahaDirector
CADLCandel Therapeutics, Inc.
Grant or award
A—
32.0K sh
Jun 23, 2026Jun 24, 2026
traded Jun 23, 2026
+1dSEC FORM 4

Evidence

  • ← Insider ofevidence
    Radhakrishnan MahaDirector · Jun 24, 2026
  • ← Insider ofevidence
    Martell ChristopherDirector · Jun 24, 2026
  • ← Insider ofevidence
    Nabel Gary J.Director · Jun 24, 2026
  • ← Insider ofevidence
    Nguyen DiemDirector · Jun 24, 2026
  • ← Insider ofevidence
    Gaeta ReneeDirector · Jun 24, 2026
  • ← Insider ofevidence
    Loggia NicolettaDirector · Jun 24, 2026